Serum levels of angiogenin (ANG) in invasive cervical cancer and in cervical intraepithelial neoplasia (CIN).
BACKGROUND
The propensity of malignant tumors to increase in size, to invade locally and to metastasize is dependent on angiogenesis, which is induced by a variety of proteins including the family of fibroblast growth factors, vascular endothelial growth factor and angiogenin (ANG). The aim of the present study was to measure the serum levels of ANG in patients with CIN and invasive cervical cancer and to evaluate a possible correlation between ANG and various clinicopathologic parameters.


METHODS
Blood was collected from 62 patients with invasive cervical cancer and 47 patients with CIN. Serum samples of 30 age-matched healthy women acting as a control group were obtained. Determination of serum levels of ANG was performed using a quantitative human ANG immunoassay.


RESULTS
The overall median ANG serum level was 272.0 pg/ml (range 101.6-869.2). The median serum levels of ANG were 248.9 (range 101.6-307.2) for healthy female controls, 246.8 (range 169.7-468.1) for patients with CIN and 308.1 pg/ml (range 180.1-869.2) for patients with invasive cervical cancer. Serum levels of ANG were significantly elevated in patients with invasive cervical cancer compared with patients with CIN (p < 0.05) as well as healthy female controls (p < 0.05). No difference was found between ANG serum levels in women with CIN, and healthy controls (p < 0.05). No correlations were found between serum levels of ANG and clinico-pathologic parameters (p > 0.05).


CONCLUSIONS
Our data indicate the important role of ANG in tumor angiogenesis in invasive cervical cancer as ANG serum levels were significantly elevated in these patients. However, elevated ANG serum levels seem to occur only after the transformation from pre-invasive to invasive lesions.
Bodner-Adler
B
B
Department of Gynecology & Obstetrics, University of Vienna Medical School, Austria.
Hefler
L
L
Bodner
K
K
Leodolter
S
S
Frischmuth
K
K
Kainz
C
C
Mayerhofer
K
K
D000230:Adenocarcinoma / Q000097:blood* / Q000098:blood supply / Q000473:pathology; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D018196:Carcinoma, Adenosquamous / Q000097:blood* / Q000098:blood supply / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000098:blood supply / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000097:blood*; D009389:Neovascularization, Pathologic / Q000097:blood; D012259:Ribonuclease, Pancreatic / Q000097:blood*; D002583:Uterine Cervical Neoplasms / Q000097:blood* / Q000098:blood supply / Q000473:pathology; D002578:Uterine Cervical Dysplasia / Q000097:blood*
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; C046366:angiogenin; D012259:Ribonuclease, Pancreatic